Perspective Therapeutics (NYSEAMERICAN:CATX) CEO Purchases $38,070.00 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) CEO Johan Spoor purchased 47,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were bought at an average cost of $0.81 per share, with a total value of $38,070.00. Following the transaction, the chief executive officer directly owned 106,383 shares of the company’s stock, valued at approximately $86,170.23. This represents a 79.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $0.83 on Thursday. Perspective Therapeutics, Inc. has a one year low of $0.78 and a one year high of $6.16. The company’s 50-day simple moving average is $2.20 and its 200-day simple moving average is $3.46. The company has a quick ratio of 6.61, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. As a group, research analysts forecast that Perspective Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

CATX has been the topic of several research analyst reports. William Blair assumed coverage on Perspective Therapeutics in a research note on Friday, September 18th. They set an “outperform” rating on the stock. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Piper Sandler dropped their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Royal Bank Of Canada downgraded shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC increased its position in Perspective Therapeutics by 34.4% in the third quarter. Voya Investment Management LLC now owns 453,650 shares of the company’s stock worth $1,248,000 after buying an additional 116,149 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after acquiring an additional 21,150 shares during the period. Provenance Wealth Advisors LLC acquired a new position in shares of Perspective Therapeutics during the third quarter valued at $44,000. Auctus Advisors LLC boosted its holdings in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after acquiring an additional 17,015 shares during the period. Finally, Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 30.3% during the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.